Serological responses to rotavirus NSP2 following administration of RV3-BB human neonatal rotavirus vaccine

Figures & data

Table 1. Serological responses to NSP2 proteins of different rotavirus strains following administration of RV3-BB or placebo.

		NSP2 protein (genogroup)
Participant #	Schedule	RV3-BB (N1)	RV4 (N1)	RV5 (N2)	SA-11 (N5)
008	Neonatal	+	+	+	+
071	Neonatal	+	+	−	−
046	Neonatal	−	−	−	−
043	Neonatal	−	−	−	−
045	Infant	+	−	+	+
086	Infant	+	−	−	+
050	Infant	−	−	−	−
075	Infant	−	−	−	−
056	Placebo	+	−	−	+
038	Placebo	+	+	+	+
014	Placebo	−	−	−	−
011	Placebo	−	−	−	−

Neonatal and Infant schedule participants received RV3-BB vaccine according to the dosing schedule described in Material and methods. (+) > 3x rise in antibody titre; (−) no serological response.

Figure 1. Titres of Anti-RV3-BB antibodies in cord blood collected at birth and in serum following dosing with RV3-BB or Placebo according to the schedule described in the Materials and methods. Serum IgA (A) and serum IgG (B) in Neonatal and Infant schedules by dose and compared to Placebo. Data points represent individual serum samples, horizontal lines represent the geometric mean titre (GMT). Data is transformed onto a natural log scale. *Significant difference between geometric mean.

Figure 2. Titres of Anti-NSP2 antibodies in cord blood collected at birth and in serum following dosing with RV3-BB or Placebo according to the schedule described in the Materials and methods. Serum IgA (A) and serum IgG (B) in Neonatal and Infant schedules by dose and compared to Placebo. Data points represent individual serum samples, horizontal lines represent the geometric mean titre (GMT). Data is transformed onto a natural log scale. *Significant difference between geometric mean.